Pharmafile Logo
Pharmafocus logo
Advanced Search

New England Journal of Medicine

Showing 2 posts of 2 posts found.

Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine

August 9, 2024
Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health

Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …

News
Xarelto

Investigation questions Xarelto trial data accuracy

February 4, 2016
Medical Communications BMJ, Bayer, INR, Johnson & Johnson, New England Journal of Medicine, Rocket-AF, Xarelto, blood clotting, rivaroxaban

The ROCKET-AF trial, the pivotal trial of the top-selling anti-clotting drug Xarelto, could have been undermined by unreliable results from …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025